Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX

MLA

Yoo Jin Choi, et al. “Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.” Gut and Liver, vol. 15, no. 3, May 2021, pp. 466–75. EBSCOhost, https://doi.org/10.5009/gnl20070.

APA

Yoo Jin Choi, Yoonhyeong Byun, Jae Seung Kang, Hyeong Seok Kim, Youngmin Han, Hongbeom Kim, Wooil Kwon, Do-Youn Oh, Woo Hyun Paik, Sang Hyub Lee, Ji Kon Ryu, Yong-Tae Kim, Kyungbun Lee, Haeryoung Kim, Eui Kyu Chie, & Jin-Young Jang. (2021). Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. Gut and Liver, 15(3), 466–475. https://doi.org/10.5009/gnl20070

Chicago

Yoo Jin Choi, Yoonhyeong Byun, Jae Seung Kang, Hyeong Seok Kim, Youngmin Han, Hongbeom Kim, Wooil Kwon, et al. 2021. “Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.” Gut and Liver 15 (3): 466–75. doi:10.5009/gnl20070.